glp 1 meds and alzheimer's Details of failed studies cast pall on Novo Nordisk's GLP-1 as treatment How GLP-1s Could Transform Alzheimer's

Specifically, a phase 2 clinical trial (NCT01839344) measured the effect of Que on glucose tolerance and postprandial endothelial function in subjects with T2D compared to the effect of an alpha-glusidase inhibitor, acarbose

tudes scientifiques

[4] A more potent, binding-protein-resistant analog such as IGF-1 LR3 would, by mechanism, be expected to retain this hypoglycemic potential, and because it evades the buffering system that normally tempers free IGF-1 activity, the metabolic effect could in principle be less predictable

Raised intracranial pressure has a direct effect on the vomiting centre leading to vomiting